ArticleAmerican journal of cancer research2026
Temporal trends in the incidence and prognosis of lung metastasis in gallbladder cancer: risk stratification and survival analysis.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung metastases are the second most common visceral metastatic site in gallbladder cancer (GBC); however, population-based evidence regarding this metastatic pattern remains limited. In this study, we sought to define the incidence trend of lung metastasis in GBC, identify risk factors associated with its occurrence, and comprehensively assess survival outcomes in this patient population. Data on GBC patients diagnosed 2010-2022 were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Joinpoint regression was used to evaluate temporal trends. Multivariate logistic regression was performed to identify independent risk factors. Overall survival (OS) was analyzed via Kaplan-Meier, multivariate Cox regression, and propensity score matching (PSM). The incidence of lung metastasis in GBC patients showed a modest but statistically significant increasing trend from 2010 to 2022, with an average annual percent change of 3.6% (95% CI 1.4%-5.8%, P<0.05). Independent risk factors for lung metastasis included advanced N stage (N1 and N2) and synchronous bone, liver, or brain metastases. GBC patients with lung metastasis exhibited poor prognosis, with a median OS of 5.0 months (95% CI 4.0-6.0). The 1-, 2-, and 3-year OS rates were 18.1%, 4.3%, and 1.0%, respectively. Isolated lung metastasis conferred better survival than concurrent other distant metastases (median OS: 7.0 vs. 4.0 months, P<0.001). Chemotherapy significantly improved survival (HR=0.39, 95% CI 0.32-0.49), whereas primary tumor resection showed no benefit after PSM. Survival rates in this population did not change significantly between 2010 and 2022. In conclusion, this comprehensive, population-based analysis provides contemporary insights into the epidemiology and management of this challenging patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.